Medivation, Inc. (MDVN: Quote) and Astellas Pharma Inc. announced that Astellas has submitted a Marketing Authorisation Application or MAA to the European Medicines Agency or EMA for enzalutamide (formerly MDV3100) for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
Enzalutamide is an oral, once-daily investigational agent that is an androgen receptor signaling inhibitor. A New Drug Application or NDA has been submitted in the United States, where priority review of the compound has been requested.
Click here to receive FREE breaking news email alerts for MEDIVATION INC and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com